Physician profile
Zachary Orme
NPI 1548880818
$1,222.23
in general payments reported to CMS, 2019-2025
20 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.30 · 2023: $178 · 2024: $471 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $381.90 | 2023-2024 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $96.40 | 2025 | Airsupra, Breztri |
| Indivior INC. | $91.05 | 2024 | Perseris, Sublocade |
| Sumitomo Pharma America, INC. | $71.45 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $64.79 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Dexcom, INC. | $60.46 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $59.66 | 2024 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.58 | 2025 | Jardiance |
| Exact Sciences Corporation | $56.38 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi Pasteur INC. | $50.54 | 2025 | |
| Merck Sharp & Dohme LLC | $42.49 | 2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Neurocrine Biosciences, INC. | $32.79 | 2024 | Ingrezza |
| Abbvie INC. | $29.31 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.95 | 2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $20.30 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20.20 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $16.49 | 2025 | |
| Lilly USA, LLC | $16.33 | 2025 | Mounjaro |
| Novo Nordisk INC | $16.26 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.90 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.